Status:
COMPLETED
A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-49 years
Phase:
EARLY_PHASE1
Brief Summary
The investigators will be looking at MAO-A density before and after seven weeks of treatment with an antidepressant and dietary supplement. MAO-A is an enzyme that breaks down brain chemicals that reg...
Detailed Description
All subjects are getting the combined treatment of a selective serotonin reuptake inhibitor and the dietary supplement. There are two possible selective serotonin reuptake inhibitor treatments but the...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of current major depressive episode and major depressive disorder
- Hamilton Depression Rating Scale score of at least 20
Exclusion
- Comorbid axis I or II disorders
- Antidepressant use in past 6 months
- Current use of herbal remedies
- Cigarette smoking
- Drug or medication use within past 8 weeks
- History of substance abuse/neurotoxin use
- History of psychotic symptoms
- History of CNS medical illness
- Current substance use
- Test positive on pregnancy test (women)
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02269540
Start Date
October 1 2014
End Date
July 1 2018
Last Update
May 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Imaging Centre, Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8